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Abstract: DICER1 syndrome is a rare genetic disorder that predisposes individuals to multiple cancer
types. Through mutations of the gene encoding the endoribonuclease, Dicer, DICER1 syndrome
disrupts the biogenesis and processing of miRNAs with subsequent disruption in control of gene
expression. Since the first description of DICER1 syndrome, case reports have documented novel
germline mutations of the DICER1 gene in patients with cancers as well as second site mutations
that alter the function of the Dicer protein expressed. Here, we present a review of mutations in
the DICER1 gene, the respective protein sequence changes, and clinical manifestations of DICER1
syndrome. Directions for future research are discussed.
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1. Introduction
DICER1 syndrome, or pleuropulmonary blastoma familial tumor susceptibility syndrome
(ORPHA: 284343; OMIM: 601200), is a rare genetic disorder predisposing individual to the development
of tumors, both benign and malignant [1–3]. Recently, mutations documented in endocrine tumors
(thyroid, parathyroid, pituitary, pineal gland, endocrine pancreas, paragangliomas, medullary,
adrenocortical, ovarian, and testicular tumors) have been reviewed [4]. One copy of the altered
gene is sufficient to cause an increased risk of developing tumors; however, many individuals who
carry a mutation in the DICER1 gene do not develop abnormal growths. Patients may acquire
a second mutation during tumorigenesis that has the potential to affect the catalytic activity of
the enzyme. The prevalence of DICER1 syndrome is currently unknown and the full spectrum of
clinical manifestation may not yet be fully defined [2,5,6]. However, documented cases of DICER1
syndrome have been linked to pleuropulmonary blastomas, cystic nephroma, rhabdomyosarcoma,
multinodular goiter, thyroid cancer, ovarian Sertoli–Leydig cell tumors, and other neoplasias [7–9].
DICER1 syndrome may also include neuroblastoma [10].
The DICER1 gene, located on chromosome 14, position q32.13, encodes the endoribonuclease Dicer
protein of the ribonuclease III family. Discovered in 2001 by Bernstein, the Dicer endoribonuclease
plays a role in protein translational control [11]. MicroRNAs (miRNAs) are created by the
Dicer endoribonuclease protein [12–14]. Dicer is a component of the RNA-induced silencing
complex (RISC) loading complex (RLC), which is composed of Dicer, Argonaute-2 (AGO2), and
trans-activation-responsive RNA binding protein 2 (TARBP2). Dicer carries out its function
downstream of DROSHA, a nuclear homolog of Dicer. miRNAs are produced from hairpin-folded
pre-miRNAs that are approximately 60 nucleotides long. The pre-miRNAs are exported to the
cytoplasm by exportin 5, where they are then processed by Dicer into the ~22 nt double stranded RNAs
(dsRNAs). dsRNAs are loaded into the Argonaut family member protein by the RLC. The resulting
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RISC asymmetrically processes the ~22 nt RNA at specific 3′-overhang and 5′-phosphate cleavage [15].
Each miRNA binds to specific mRNAs, inhibiting ribosomal access and subsequent translation to
control gene expression [16] (see Figure 1). miRNA-mediated effects that lead to DICER1 syndrome
may be due to loss-of-function in genes that normally contribute to the prevention of cancer (tumor
suppressors), or alternatively, changes that lead to gain of function in genes that contribute to the
onset of cancer in an active manner (oncogenes) [17]. Dysregulation of miRNA production is related
to several tumor types [18]. Mutations in the DICER1 gene are found in approximately 50–70% of
pleuropulmonary blastoma patients [1].
Figure 1. miRNA Production Pathway. DNA sequences are transcribed into RNA sequences that form
a ‘hairpin’ structure of precursor miRNA. Drosha, a nucleic endoribonuclease, cleaves the hairpin from
the primary RNA strand. Transported out of the nucleus by exportin 5, they are further processed
by Dicer. After processing by Dicer and its accessory proteins, the hairpin structure of the precursor
miRNA is degraded, leaving a single, linear piece of miRNA (the opposing piece is degraded by
intracellular processes). This single piece is then bound by the RNA-induced silencing complex RISC.
The RISC-miRNA complex binds to target mRNA strands, inhibiting translation by the ribosome.
Dicer plays additional diverse roles other than miRNA regulation [19]. Dicer plays a role in the
processing of rRNA and, indirectly, ribosome biogenesis prior to export from the nucleus. In addition,
Dicer plays a role in DNA processing and apoptosis [20]. Upon initiation of apoptosis, Dicer initiates
the breakdown of chromosomal DNA, a key step in controlled cell death.
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2. DICER1 Germline Mutations
Research into the causal factors and mechanisms of DICER1 syndrome has been represented in
the scientific literature since 2009. Generation and dissemination of new knowledge about DICER1
syndrome is increasing as demonstrated by the increasing number of publications each year over the
past decade. Mutations that lead to DICER1 syndrome are reviewed here.
Pathogenic germline mutations of the DICER1 gene linked to DICER1 syndrome are included in
this review. Case studies provided detailed information regarding the germline mutation, patient(s),
and physical manifestation. Mosaic DICER1 mutations have also been associated with DICER1
syndrome [21], in addition to the inherited germline mutations. Cases represented in the PubMed
database [22] were identified using keywords “DICER1 syndrome”, “DICER1 mutations”, and
“Pleuropulmonary Blastoma Familial Tumor Susceptibility Syndrome”. A total of 244 articles were
collected since the discovery of DICER1 syndrome, and 36 were selected that represented DICER1
pathogenic germline mutations. Articles were excluded from this review if they did not address
germline mutations in the DICER1 gene, if they did not identify novel mutations, or if detailed
documentation was absent from the report.
Eighty-eight DICER1 mutations are included in this review. While the majority of identified
mutations are located within regions that encode one of Dicer’s seven defined domains (helicase
domains, the Dicer dimerization domain (DDD), the Piwi/Argonaute, Zwille (PAZ) domain, the
RNase III domains, and the double-stranded RNA-binding domain), some mutations were found to lie
outside these domains (see Figure 2). Mutations, resulting protein changes, patient information, and
background, clinical manifestation, and references are presented in Tables 1–3.
Figure 2. DICER1 Pathogenic Germline Mutations. Mutations reported in DICER1 include deletions,
duplications, insertions, transitions, or transversions. The DICER1 gene encodes 1922 amino acids,
arranged into specific domains including the helicase 1/2, ATP-binding domain, the helicase,
C-terminal domain, the Dicer dimerization domain (DDD), the PAZ domain (PAZ), the ribonuclease
IIIa domain, and the ribonuclease IIIb domain. (see Tables 1–3).
3. Manifestations of DICER1 Gene Mutations
While the range of clinical symptoms associated with DICER1 syndrome is varied, some
symptoms are prevalent among patients. These include multinodular goiter, pleuropulmonary
blastoma, cystic nephroma, and ovarian Sertoli–Leydig Cell Tumor.
3.1. Multinodular Goiter (MNG)
Multinodular goiters, abnormal, cancerous growths of the thyroid gland, are associated with
DICER1 syndrome and are a subsection of thyroid growths, which have been reported as a prevalent
manifestation of DICER1 syndrome. Seventy-five percent of women and 17% of men with DICER1
syndrome were shown to harbor abnormal thyroid growths, multinodular goiters included, compared
to the control population: 8% and 0% for women and men, respectively [23]. Specifically, a recent study
indicated a correlation between truncating germline DICER1 mutations and familial multinodular
goiter, among other cancers [24]. Women are more likely to develop thyroid cancer than men, regardless
of DICER1 variant status [25]. Frequent malignant neoplasms of the endocrine system [26] such as
thyroid cancers are linked to both environmental and genetic factors, with studies indicating similar
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links between multinodular goiters and both environmental and genetic factors [27]. DICER1 mutations
and subsequent global downregulation of miRNAs were found in multinodular goiter [28].
3.2. Pleuropulmonary Blastoma
Pleuropulmonary blastoma is a manifestation of DICER1 syndrome [29]. Primarily observed in
children, it is a rare cancer that originates in the pleural cavity or the lungs [30]. Although rare, many
cases of pleuropulmonary blastoma have been identified to be associated with DICER1 syndrome.
First described in 1988 [31], cases are now documented in an international registry.
Four types of pleuropulmonary blastomas have been characterized. Type I is defined by cystic
growths, has malignant potential, and may undergo malignant transformation in childhood. Type Ir is
very similar to Type I, being defined by cystic growths, but contains no cancerous cells and is therefore
not malignant. Type II consists of a hybrid of cystic and cancerous tumors, and type III solely consists
of solid cancerous tumors. Types II and III have been associated with increased metastasis, primarily
to the brain [32], and were found to be more aggressive than type I pleuropulmonary blastomas [33]
(See Table 1).
Table 1. Pathogenic germline mutations in the DICER1 gene related to Pleuropulmonary Blastoma.
Mutation
Type Chromosomal Mutation Protein Change Clinical Manifestation Reference
dup c.1196_1197dupAG p.Trp400Serfs*59 4-year old, pleuropulmonary blastoma. Slade, 2011 [7]
tran c.1376+1G>A p.splice
13-year old female, peritoneal cysts of
right & left round ligaments, nasal
polyps, Sertoli–Leydig cell tumor.
History: 5 years, type II pleuropulmonary
blastoma, 8 years, thyroid nodules.
Schultz, 2016 [34]
tran c.1507G>T p.Glu503* pleuropulmonary blastoma. Hill, 2009 [1]
del c.1684_1685delAT p.Met562Valfs*11 pleuropulmonary blastoma. Hill, 2009 [1]
del c.1716delT p.Phe572Leufs*15 0.8-year old, pleuropulmonary blastoma. Slade, 2011 [7]
dup c.1910dupA p.Tyr637*
5-month old female, pleuropulmonary
blastoma, and cervical embryonal
rhabdomyosarcoma; pleuropulmonary
blastoma & embryonal
rhabdomyosarcoma.
Hill, 2009 [1];
Doros, 2012 [35]
tran c.1966C>T p.Arg656* pleuropulmonary blastoma; 7-year old,pleuropulmonary blastoma.
Slade, 2011 [7]
Hill, 2009 [1]
tran c.2040+1G>T p.splice
10-year female, nasal
chondromesenchymal hamartoma.
History: Pleuropulmonary blastoma.
Stewart, 2014 [36]
dup c.2245_2248dupTACC p.Pro750Leufs*12 pleuropulmonary blastoma. Hill, 2009 [1]
tran c.2247C>A p.Tyr749* pleuropulmonary blastoma. Hill, 2009 [1]
del c.2268_2271delTTTG p.Cys756* 0.9-year old, pleuropulmonary blastoma. Slade, 2011 [7]
tran c.2379T>G p.Tyr793*
11.5-years male, bilateral papillary
thyroid carcinoma in follicular adenoma.
History: 32 months, type II
pleuropulmonary blastoma and
cystic nephroma.
de Kock, 2014 [37]
dup c.2392dupA p.Thr798Asnfs*33 pleuropulmonary blastoma. Hill, 2009 [1]
del c.2399delG p.Arg800fs*5 3.5-year old and 13-year old,Wilms’ tumor. Palculict, 2016 [38]
tran c.2830C>T p.Arg944* pleuropulmonary blastoma. Hill, 2009 [1]
del c.2863delA p.Thr955fs
7-year old male, nasal
chondromesenchymal hamartoma.
History: pleuropulmonary blastoma.
Stewart, 2014 [36]
tran c.3019C>T p.Gln1007*
27-year old woman, nasal
chondromesenchymal hamartoma and
pleuropulmonary blastoma. History:
multinodular goiter.
Stewart, 2014 [36]
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Table 1. Cont.
Mutation
Type Chromosomal Mutation Protein Change Clinical Manifestation Reference
del c.3505delT p.Ser1169Glnfs*23 3-year-old, Pleuropulmonary blastoma. Slade, 2011 [7]
dup c.3505dupT p.Ser1169Phefs*8
7-year old female, thyroid goiter, multiple
nodules on both lobes. History: 4.3 years,
pleuropulmonary blastoma in left back
musculature. 23 months, type II
pleuropulmonary blastoma.
de Kock, 2014 [37]
tran c.3540C>A p.Tyr1180* pleuropulmonary blastoma. Hill, 2009 [1]
del c.3583_3584delGA N/A
6-year-old, intraocular
medulloepithelioma. History:
pleuropulmonary blastoma.
Slade, 2011 [7]
del c.3665delT p.Leu1222Tyrfs*17 4.2-year old, pleuropulmonary blastoma. Slade, 2011 [7]
tran c.3726C>A p.Tyr1242*
4-year old, pleuropulmonary blastoma;
27-year old female, pleuropulmonary
blastoma. History: 13 years,
Sertoli–Leydig cell tumor and
multinodular goiter, 21 years, nasal
chondromesenchymal hamartoma.
Slade, 2011 [7];
Stewart, 2014 [36]
del c.4309_4312delGACT p.Asp1437Metfs*16
8-year old female, embryonal
rhabdomyosarcoma. History: 4 years,
pleuropulmonary blastoma; Median Age
34 months, female, cystic nephroma,
pleuropulmonary blastoma.
Doros, 2012 [35];
Bahubeshi, 2010 [39]
del c.4403_4406delCTCT p.Ser1468Phefs*21 1.5-year old, pleuropulmonary blastoma. Slade, 2011 [7]
del c.4407_4410delTTCT p.Leu1469fs
11-year old male, nasal
chondromesenchymal hamartoma.
History: pleuropulmonary blastoma.
Stewart, 2014 [36]
del c.4555delG p.Glu1519Lysfs*41 3-year old female, Polish, type IIpleuropulmonary blastoma. de Kock, 2013 [40]
tran c.4616C>T p.Thr1539Met
11-year-old male, Hodgkin lymphoma,
pleuropulmonary blastoma Type I.
History: thyroid cysts, syringomyelia.
Kuhlen, 2016 [41]
tran c.4748T>G p.Leu1583Arg pleuropulmonary blastoma. Hill, 2009 [1]
tran c.5104C>T p.Gln1702* 9-year old female, pleuropulmonaryblastoma & ERMS. Doros, 2012 [35]
del c.5221_5232delAACAACACCATC p.Asn1741_1744del
9-year old male, multinodular goiter,
pleuropulmonary blastoma. History: 20
months, cystic nephroma.
Rath, 2014 [42]
del c.5299delC premature stop inexon 24
11-year-old male, Hodgkin lymphoma,
pleuropulmonary blastoma Type I.
History: thyroid cysts, syringomyelia.
Kuhlen, 2016 [41]
tran c.5387C>T p.Gln1783*
14-month old female, type I
pleuropulmonary blastoma. History:
cystic nephroma.
Fernandez-Martinez,
2017 [43]
tran c.5465A>T p.Asp1822Val 1.8-year-old, pleuropulmonary blastoma. Slade, 2011 [7]
tran c.5477C>A p.Ser1826* Median Age 34 months, female, cysticnephroma, pleuropulmonary blastoma. Bahubeshi, 2010 [39]
del—deletion, dup—duplication, tran—transversion/transition.
3.3. Cystic Nephroma
Cystic nephromas have been reported in approximately 12% of children with pleuropulmonary
blastomas or those with a family member with cystic nephroma [44,45]. The frequency of DICER1
germline mutations in cystic nephroma patients was found to be 73.2% [46,47].
Cystic nephromas, multilocular cystic nephroma, and cystic renal hamartoma [48] are benign
lesions in the kidney [49]. Common symptoms include hematuria, flank pain, and increased abdominal
mass [50]. Enucleation of characteristic cysts can be associated with recurrence [51]. Treatment includes
radical nephrectomy to prevent renal cell carcinoma [48].
A recent study of a patient with a cystic nephroma diagnosed as a multicystic left renal tumor
was diagnosed with germline and somatic mutations in the DICER1 gene [52]. Additionally, a nascent
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anaplastic sarcoma of the kidney (ASK) was reported within a cystic nephroma, associated with the
presence of a germline DICER1 mutation, or alternatively due to a somatic mutation [44,53].
3.4. Sertoli–Leydig Cell Tumor
Ovarian sex cord-stromal tumors have been associated with DICER1 mutations [54,55], specifically,
ovarian Sertoli–Leydig cell tumors. While rare among all ovarian neoplasms (<0.5%) [56], a recent
study indicated that 57% of individuals with ovarian Sertoli–Leydig cell tumors also harbored DICER1
germline mutations [46]. Another study confirmed this, indicating that more than 60% of ovarian
Sertoli–Leydig cell tumors diagnosed harbored DICER1 mutations within the RNase III domains [57].
A more recent study examined 34 Sertoli–Leydig cell tumors, with 88% containing one-or-more DICER1
mutations [58].
Ovarian Sertoli–Leydig cell tumors are composed of several cell types, including Sertoli cells
and Leydig cells [59]. They are responsible for an increase in testosterone production [60], and can
lead to masculinization, voice deepening, and acne [61]. Interestingly, a recent study noted that the
simultaneous occurrence of Sertoli–Leydig cell tumor and thyroid carcinoma is a reliable indicator of
DICER1 syndrome [62] (See Table 2).
Table 2. Pathogenic germline mutations in the DICER1 gene related to Sertoli–Leydig Cell Tumor.
Mutation
Type Chromosomal Mutation Protein Change Clinical Manifestation Reference
tran c.325C>T p.Gln109* 11-year old female, multinodular goiter.History: Sertoli–Leydig cell tumor. Canfarotta M, 2016 [5]
del c.876_879delAAAG p.Arg293Ilefs*4 18-year old female, Sertoli–Leydig cell tumor.History: 16 years, multinodular goiter. Rio Frio, 2011 [8]
tran c.1376+1G>A p.splice
13-year old female, peritoneal cysts of right &
left round ligaments, nasal polyps,
Sertoli–Leydig cell tumor. History: 5 years,
type II pleuropulmonary blastoma, 8 years,
thyroid nodules.
Schultz, 2016 [34]
del c.1532_1533delAT N/A
28-year old female, Sertoli–Leydig cell tumor.
History: None | 16-year-old, Sertoli–Leydig
cell tumor.
Oost, 2015 [63]
tran c.2457C>G p.Ile813_Tyr819del 32-year old female, Sertoli–Leydig cell tumor.History: 18 years, multinodular goiter. Rio Frio, 2011 [8]
del/ins c.3270-6_4051—1280delinsG p.Tyr1091Ser*28
14-year old female, multinodular goiter.
History: Sertoli–Leydig cell tumor, primitive
neuroectodermal tumor.
Sabbaghian, 2013 [64]
tran c.3540C>A p.Tyr1180*
16-year old female, Sertoli–Leydig cell tumor.
History: 14 years, bilateral multinodular goiter.
16-year old female, ovarian Sertoli–Leydig cell
tumor, and lung lesion. History: 14 years,
multinodular goiter.
de Kock, 2016 [65]
Wu, 2014 [66]
tran c.3647C>A p.Ser1216* 13-year old female, Danish, multinodulargoiter and Sertoli–Leydig cell tumor. Rossing, 2014 [67]
tran c.3649T>A p.Tyr1217Asn 13-year old female, Danish, multinodulargoiter and Sertoli–Leydig cell tumor. Rossing, 2014 [67]
tran c.3726C>A p.Tyr1242*
27-year old female, pleuropulmonary blastoma.
History: 13 years, Sertoli–Leydig cell tumor
and multinodular goiter, 21 years, nasal
chondromesenchymal hamartoma.
Stewart, 2014 [36]
del c.4050+1delG p.Val351Valfs*11
20-year old female, primitive neuroectodermal
tumor & multinodular goiter. History: 9 years,
Sertoli–Leydig cell tumor.
Foulkes, 2011 [68]
del c.5018_5021delTCAA p.Ile1673Thrfs*31 32-year old female, Sertoli–Leydig cell tumor.History: 18 years, multinodular goiter. Rio Frio, 2011 [8]
del c.5122_5128delGGAGATG p.Gly1708Argfs*7 21-year old, Sertoli–Leydig cell tumor. History:17 years, Sertoli–Leydig cell tumor. Slade, 2011 [7]
del—deletion, dup—duplication, tran—transversion/transition.
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4. Additional Symptoms and Presentations Related to DICER1 Syndrome
4.1. Hodgkin Lymphoma
DICER1 syndrome includes novel symptoms which may facilitate early diagnosis. A rare form
of Hodgkin lymphoma was diagnosed in an 11-year old boy with DICER1 syndrome in 2016 [41].
The patient had two DICER1 mutations (c.5299delC and c.4616C>T), and several of his family members
shared these mutations. Prior to this diagnosis, Hodgkin lymphoma had not been linked to DICER1
syndrome; additionally, this form of Hodgkin lymphoma is considered rare. Most Hodgkin and
Reed–Sternberg cells arise from mature B cells, but a rare subset of cells arise from T cells. In this
patient, the cells were found to be of the T-cell lineage, indicating a unique symptom. All affected
family members developed at least one type of tumor with differing origins [5].
4.2. Pineoblastoma
Pineoblastoma may be associated with a DICER1 mutation. Individuals with pineoblastomas were
tested by de Kock and colleagues for the presence of DICER1 mutations. They suggested that germline
DICER1 mutations make a clinically significant contribution to pineoblastoma; however, additional
studies may confirm a causal relationship [69]. Additionally, the study of a single patient implicated
a DICER1 germline mutation in a pineoblastoma. The mutation was found to be heterozygous for
germline but hemizygous in the tumor itself [70]. Further studies may determine the relationship
between DICER1 mutations and pineoblastomas (See Table 3).
Table 3. Pathogenic germline mutations in the DICER1 gene related to cystic nephroma, pineoblastomas,
Wilms’ tumor, multinodular goiter, medulloblastoma, rhabdomyosarcoma, pituitary blastoma,
endometrial cancer, and seminoma.
Mutation
Type Chromosomal Mutation Protein Change Clinical Manifestation Reference
dup c.328_338dupGTGTCAGCTGT p.Arg114Cysfs*18 3-year old, cystic nephroma. Slade, 2011 [7]
dup c.912_919dupAGACTGTC p.Arg307Glnfs*8 4-year old male, Wilms’ tumor. Foulkes, 2011 [68]
del c.1128_1132delAGTAA p.Lys376Asnfs*11 Pineoblastomas. Sabbaghian, 2012 [70]
del c.1153delC p.Arg385Alafs*73 13-year old, Medulloblastoma/infratentorialprimitive neuroectodermal tumor. Slade, 2011 [7]
dup c.1196_1197dupAG p.Trp400Serfs*59
16-year old female, Ashkenazi
Jewish/Anglo-Saxon, fibroadenoma of the
breast. History: 6 years, ovarian embryonal
rhabdomyosarcoma, 11 years, radiologic
focal nodular liver hyperplasia, 12 years,
cystic nephroma, 13 years,
multinodular goiter.
de Kock, 2015 [71]
del c.1284delGA N/A 23-month old female, pituitary blastoma de Kock, 2014 [72]
dup c.1306dupT p.Ser436Phefs*41 2-year old male, Wlims’ tumor. Foulkes, 2011 [68]
tran c.1525C>T p.Arg509* 12-year old female, multinodular goiter.History: 6 years, dermoid cyst. Darrat, 2013 [28]
tran c.1966C>T p.Arg656*
15-month old female, Pulmonary
sequestration & cystic nephroma.
14-year old female, Belarusian-Serbian,
hepatic focal nodular hyperplasia. History:
Right Brain ventricle tumor (part teratoma,
party embryonic carcinoma) at 8 months old.
pilomatrixoma at 3 years, Renal cysts at
4 years, thyroid nodules at 10 years, basal cell
carcinoma at 13 years.
Foulkes, 2011 [68]
Mehraein, 2016 [73]
tran c.2026C>T N/A 17-year old female, pituitary blastoma. de Kock, 2014 [72]
tran c.2062C>T p.Arg688*
8 year, a 9-month-old girl, anaplastic sarcoma
of the kidney. History: pneumothorax, left
upper lung cyst and left renal cyst at
10 months. cysts multiplied and increased in
size over next few years.
Wu, 2016 [74]
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Table 3. Cont.
Mutation
Type Chromosomal Mutation Protein Change Clinical Manifestation Reference
tran c.2117-1G>A p.Gly706Aspsfs*8 10-year old female, multinodular goiter.History: 5 years, Wilms’ tumor. Foulkes, 2011 [68]
tran c.2247C>A p.Tyr749* 6-week old male, embryonalrhabdomyosarcoma. Doros, 2012 [35]
del c.2399delG p.Arg800fs*5 3.5-year old and 13-year old, Wilms’ tumor. Palculict, 2016 [38]
tran c.2407G>A p.Gly803Arg The average age of 44 months, Wilms’ tumor. Palculict, 2016 [38]
del c.2450delC p.Pro817Leufs*15
7-month old female, Polish, multiseptated
cystic mass in abdomen (early
anaplastic sarcoma).
Wu, 2016 [52]
tran c.2455T>C p.Tyr819His 34 & 32-year old male family members,hepatocellular tumors. Caruso, 2016 [75]
tran c.2457C>G p.Ile813_Tyr819del 53-year-old female, cERMS. History:multinodular goiter. de Kock, 2015 [76]
tran c.2516C>T p.Ser839Phe 15-year old female, multinodular goiter. Rio Frio, 2011 [8]
tran c.2805-1G>T p.Tyr936_Arg996del
The patient died at 20 years from alveolar
rhabdomyosarcoma. History:
multinodular goiter.
Rio Frio, 2011 [8]
del c.3046delA p.Ser1016Valfs*1065 12-month old female, pituitary blastoma. Sahakitrungruang,2014 [77]
tran c.2379T>G N/A 3-year old male, pituitary blastoma. de Kock, 2014 [72]
del c.3277_3280delAACT N/A 7-year old female, pituitary blastoma. de Kock, 2014 [72]
ins c.3288_3289insTTTC p.Gly1097Phefs*8 1.5-year old, cystic nephroma. Slade, 2011 [7]
tran c.3334A>G p.Asn1112Asp 55-year old female, endometrial cancer. Yang, 2015 [78]
dup c.3405dupA p.Gly1136Arg
12-year old female, renal cysts & focal
nodular hyperplasia of the liver. History:
6 months, eRMS of the bladder and a cystic
lesion in the lung at. 3 & 4.5 years, Ciliary
body medulloepithelioma.
Fremerey, 2016 [79]
del c.3535_3538delTCTT p.Ser1179Thrfs*12 13-year old female, cervicalsarcoma botryoides. Tomiak, 2014 [80]
tran c.3540C>G p.Tyr1180
2-year old female, a multilocular cyst in left
kidney, 2 cystic lesions in the lung,
multicystic nephroma extended from
left kidney.
Bardon-Cancho, 2016
[81]
del c.3611_3616delACTACAinsT p.Tyr1204Leufs*29 14-year old female, cERMS andthyroid goiter. Foulkes, 2011 [68]
dup c.3665dupT p.Leu1222fs*13 30–39 year old female, soft tissue sarcoma de Kock, 2017 [9]
del c.3793delA p.Thr1265Glnfs*37 6-year-old, ovarian sex cord stromal tumour. Slade, 2011 [7]
del c.3907_3908delCT p.Leu1303Valfs*4
13-year old female, cervical embryonal
rhabdomyosarcoma & two small lung cysts.
History: 11 years, multinodular goiter.
Foulkes, 2011 [68]
del c.4309_4312delGACT N/A Male, deceased 8 months post-surgery,pituitary blastoma. de Kock, 2014 [72]
dup c.4566_4579dupCTTTG p.Val1524fs*38 14-month old female, neuroblastoma & cysticnephroma, multinodular goiter at age 7. Saskin, 2017 [10]
tran c.4740G>T p.Gln1580His 32-year old, seminoma. Slade, 2011 [7]
tran c.5096-12G>A N/A 10-year old female, undifferentiated sarcomaat ovary. de Kock, 2017 [9]
tran c.5125G>C(de novo) N/A 21-month old male, pituitary blastoma. de Kock, 2014 [72]
del c.5221_5232delAACAACACCATC p.Asn1741_1744del
9-year old male, multinodular goiter,
pleuropulmonary blastoma. History:
20 months, cystic nephroma.
Rath, 2014 [42]
del/ins
c.5426_5442 del
GGGATATTTTT
GAGTCGinsCA
p.Gly1809_
Ser1814delinsAla
15-year old female, thyroid follicular
carcinoma. History: ASK for 12 years &
multiple cystic-appearing thyroid nodules,
no malignancy.
Yoshida, 2017 [82]
tran c.5441C>T p.Ser1814Leu 12.5-year-old female, ovarian tumor. History:12 years, multinodular goiter. Wu, 2016 [83]
del—deletion, dup—duplication, tran—transversion/transition.
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4.3. Global Developmental Delay, Lung Cysts, Overgrowth, and Wilms Tumor (GLOW)
Documented by Klein and colleagues, symptoms include Global developmental delay, Lung
cysts, Overgrowth, and Wilms tumor (GLOW). These symptoms were identified in patients with
DICER1 mutations in the RNase IIIb domain of Dicer [84]. Mutations were associated with Lung cysts
and Wilms tumors, but also developmental delays and overgrowth, marked by large body size and
mass. While both mutations reported were de novo missense mutations, the symptoms were similar
to that of other patients diagnosed with germline mutations in similar loci within the DICER1 gene.
The current understanding of GLOW syndrome is limited, and more inquiry is required to determine
how widespread GLOW syndrome is in relation to DICER1 syndrome.
4.4. Macrocephaly
A recently conducted study indicated that macrocephaly is associated with DICER1 syndrome [85].
Further studies are needed to confirm the link between macrocephaly and DICER1 syndrome, as this
may help to identify individuals with DICER1 syndrome at an early stage.
5. Molecular Mechanisms of DICER1 Mutations—The Two-Hit Hypothesis
The two-hit hypothesis, also known as the Knudson hypothesis, was originally suggested in 1953,
and formally postulated by Knudson in 1971 [86,87]. The hypothesis suggests that, for abnormalities
to arise, an individual requires two separate mutations in each allele, and that only one mutation
in a single allele is not sufficient to induce the formation of tumors. Generally, a single mutation is
inherited, which by itself is relatively harmless. However, a second mutation may act in tandem with
the first to give rise to cancer. In a number of cases, the two-hit hypothesis describes the mechanism by
which tumor suppressor gene deactivation occurs [88,89].
DICER1 syndrome has been recognized as an autosomal-dominant disease, inherited and
expressed in a haploinsufficient manner [1,5]. This proposed mechanism has been substantiated
by a number of cases of individuals with DICER1 syndrome. Specifically, these cases involved
individuals with only one apparent germline mutation, and symptoms characteristic of DICER1
syndrome. However, recent studies have indicated that patients with DICER1 syndrome have not
only inherited mutations in one allele of the DICER1 gene but also acquired a somatic mutation in the
second allele of the DICER1 gene. The two-hit hypothesis applies to DICER1 mutations and the role of
Dicer as a tumor suppressor gene (see Figure 3).
Second-hit, somatic mutations have been found in the RNase IIIb domain of the DICER1 gene.
A study involving three children with Wilms’ tumor suggested that the two-hit hypothesis applied to
DICER1 syndrome, in the formation of Wilms’ tumor [90]. The patients were found to harbor germline
DICER1 mutations, and upon screening for somatic DICER1 mutations, somatic mutations in the
RNase IIIb domain on the second allele were found. Additionally, this finding highlights DICER1
somatic gene mutations occurring in Wilms Tumor patients in the RNase IIIb domain. The regions
of the gene encoding the RNase III domains are genetic hotspots for somatic mutations within the
DICER1 gene [91,92].
Biallelic DICER1 mutations are common in pleuropulmonary blastomas, with the second mutation
occurring within the RNase IIIb domain [93]. A study on 11 pleuropulmonary blastoma patients
revealed that, out of 11 patients with DICER1 gene mutations with sporadic pleuropulmonary
blastomas, eight harbored biallelic DICER1 gene mutations in which one of the mutations was within
the RNase IIIb domain.
A recent report of biallelic DICER1 mutations in an ovarian fibrosarcoma from a 9-year-old patient
demonstrated a germline single base insertion in the DICER1 gene, causing a frameshift and premature
stop codon as well as a second point mutation within the tumor that resulted in a substitution at amino
acid position 1813 within the RNase IIIb domain (p.E1813G) [94].
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Figure 3. The two-hit hypothesis. One germline mutation in a DICER1 allele predisposes the individual
to an increased risk for benign and malignant tumors. A second somatic mutation in the other allele
arising during tumorigenesis may lead to malignant rare cancers. While the first mutation by itself is
overtly harmless, it only acts in tandem with the second to induce cancerous formation, according to
the hypothesis.
Another case study involved a 14-month-old female patient diagnosed with pleuropulmonary
blastoma and a previously removed cystic nephroma at 11 months [43]. Mutation analysis was
conducted on available tissue and peripheral blood, revealing both alleles of the DICER1 gene to
be compromised. A missense heterozygous somatic mutation (c.5425G>A; p.G1809R) was detected
in the DNA obtained from the cystic nephroma in addition to the germline truncating mutation
detected from peripheral blood (c.5347C>T; p.Q1783*) within exon 24, which encodes the RNase IIIb
domain. This germline mutation was confirmed in the patient’s mother and grandmother. In addition,
the patient’s 21-year-old female cousin was found to also harbor the germline mutation and had
previously been treated for embryonal rhabdomyosarcoma at age 14 and multimodal goiter at age 20.
A unique missense heterozygous somatic mutation was detected in the embryonal rhabdomyosarcoma
(c.5428G>C; p.D1810H) from a cousin of the patient. This case demonstrates that biallelic mutations in
DICER1 alleles, rather than haploinsufficiency, contribute to the mechanism of DICER1 syndrome.
Brenneman and colleagues [95] discussed the concept of biallelic mutations of the DICER1 gene,
with a focus on second, somatic, hot-spot mutations in the RNase IIIb domain. A cohort of individuals
diagnosed with pleuropulmonary blastoma underwent analysis to determine the mutation status of
DICER1 alleles. Mutations within the RNase IIIb domain may represent hotspot mutations [96], and
may be the rate-limiting step in the pathogenesis of DICER1 syndrome. Loss of function germline
mutations in one allele of DICER1 was found to be common among patients, and the RNase IIIb hotspot
mutations were less common, but more frequently found within the tumor. RNase IIIb mutations may
also predispose patients to additional mutations due to the role of Dicer in DNA replication and repair.
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6. Future Directions
The breadth of knowledge regarding DICER1 syndrome continues to grow since its recent
discovery, but promising treatments and management options need further investigation. As Dicer
deficiency stems from DICER1 mutations, experiments on Dicer in model animals have attempted
to determine viable methods of upregulation of Dicer and related proteins to combat the effects of
DICER1 syndrome. One such study conducted by Blandino and colleagues treated diabetic mice with
metformin, reducing the incidence of cancer [97]. Mice treated with metformin showed reduced tumor
growth and an upregulation of miRNAs and an increase in DICER1 gene expression. A similar, recent
experiment confirmed these results, as metformin was found to induce higher Dicer levels in mouse
models and human patients by altering the localization of AUF1, a DICER1 mRNA binding protein that
down-regulates DICER1, leading to increased DICER1 mRNA stability [98,99]. While the treatments
described in these experiments may not be beneficial to patients with biallelic DICER1 mutations,
those with a single, functional DICER1 allele might benefit from metformin and compounds similar to
it, as this single allele could hypothetically be targeted and upregulated to achieve increased Dicer
protein production.
DICER1 germline mutations have been identified as nonsense mutations, leading to stop
codons within the coding sequence and truncated proteins or nonsense-mediated RNA degradation.
While these mutations lead to cancerous and non-cancerous tumors, certain antibiotic treatments
have been shown to promote the read-through of similar premature stop-codons, leading to restored
transcription and translation of otherwise unreadable sequences [100]. One study demonstrated
this novel approach by treating human cells containing known nonsense mutations with Ataluren,
a pharmaceutical drug utilized in treating genetic disorders. Ataluren successfully promoted the
read-through of all three nonsense codons within the mutated alleles [101]. A more recent study
built upon these findings by modifying the fluorine number and position of Ataluren, which led to
the increased read-through ability of stop codons in nonsense mutations [102]. While no research
has been conducted on DICER1 nonsense mutations utilizing drugs such as Ataluren, this drug and
synonymous compounds may prove beneficial in treating patients with DICER1 syndrome stemming
from nonsense mutations similar to those already tested. While treatments for pleuropulmonary
blastoma and cystic nephroma have received wide attention from the scientific community, the root
of these abnormal formations, DICER1 germline mutations and acquired somatic mutations, require
more study.
7. Conclusions
The mechanisms of DICER1 syndrome and its presentation in patients have become more fully
understood over the past several years as more cases are diagnosed with novel mutations and
presentations discovered and documented, extending the phenotypic range of this disorder. Successful
treatments for DICER1 syndrome will require a combination of basic, translational, and clinical research.
The outcome of the inaugural International DICER1 Symposium was the development of consensus
testing and surveillance as well as treatment recommendations. Recommendations for genetic
testing—including intronic sequencing [103]; whole exome sequencing [104]; or screening products
such as the ThyroSeq, which is a DNA- and RNA-based next-generation sequencing assay that analyzes
112 genes for genetic alterations, including point mutations, insertions/deletions, gene fusions,
and copy number alterations [105], prenatal management—and surveillance for DICER1-associated
symptoms have been developed and described in recent publications [106–108].
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Abbreviations
AGO2 argonaute-2
AUF1 heterogeneous nuclear ribonucleoprotein D
DDD Dicer dimerization domain
GLOW Global developmental delay, Lung cysts, Overgrowth, and Wilms tumor
miRNAs MicroRNA
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RISC RNA-induced silencing complex
RLC RNA-induced silencing complex (RISC) loading complex
RNase IIIb ribonuclease IIIb
rRNA ribosomal RNA
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References
1. Hill, D.A.; Ivanovich, J.; Priest, J.R.; Gurnett, C.A.; Dehner, L.P.; Desruisseau, D.; Jarzembowski, J.A.;
Wikenheiser-Brokamp, K.A.; Suarez, B.K.; Whelan, A.J.; et al. DICER1 mutations in familial pleuropulmonary
blastoma. Science 2009, 325, 965. [CrossRef] [PubMed]
2. Orphanet: Pleuropulmonary Blastoma Familial Tumor Susceptibility Syndrome. Available online:
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=64742 (accessed on 19 April 2017).
3. DICER1 Syndrome|Children’s Hospital of Philadelphia. Available online: http://www.chop.edu/
conditions-diseases/dicer1-syndrome (accessed on 19 April 2017).
4. Solarski, M.; Rotondo, F.; Foulkes, W.D.; Priest, J.R.; Syro, L.V.; Butz, H.; Cusimano, M.D.; Kovacs, K. DICER1
gene mutations in endocrine tumors. Endocr. Relat. Cancer 2018, 25, R197–R208. [CrossRef] [PubMed]
5. Canfarotta, M.; Riba-Wolman, R.; Orsey, A.D.; Balarezo, F.; Finck, C. DICER1 syndrome and thyroid disease.
J. Pediatr. Surg. Case Rep. 2016, 11, 31–34. [CrossRef]
6. DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome|Genetic and Rare Diseases
Information Center (GARD)—An NCATS Program. Available online: https://rarediseases.info.nih.gov/
diseases/10734/dicer1-related-pleuropulmonary-blastoma-cancer-predisposition-syndrome (accessed on
19 April 2017).
7. Slade, I.; Bacchelli, C.; Davies, H.; Murray, A.; Abbaszadeh, F.; Hanks, S.; Barfoot, R.; Burke, A.; Chisholm, J.;
Hewitt, M.; et al. DICER1 syndrome: Clarifying the diagnosis, clinical features and management implications
of a pleiotropic tumour predisposition syndrome. J. Med. Genet. 2011, 48, 273–278. [CrossRef] [PubMed]
8. Rio Frio, T.; Bahubeshi, A.; Kanellopoulou, C.; Hamel, N.; Niedziela, M.; Sabbaghian, N.; Pouchet, C.;
Gilbert, L.; O’Brien, P.K.; Serfas, K.; et al. DICER1 mutations in familial multinodular goiter with and without
ovarian Sertoli-Leydig cell tumors. JAMA 2011, 305, 68–77. [CrossRef] [PubMed]
9. De Kock, L.; Rivera, B.; Revil, T.; Thorner, P.; Goudie, C.; Bouron-Dal Soglio, D.; Choong, C.S.; Priest, J.R.;
van Diest, P.J.; Tanboon, J.; et al. Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1
mutations in an adult-onset embryonal rhabdomyosarcoma. Br. J. Cancer 2017, 116, 1621–1626. [CrossRef]
[PubMed]
10. Saskin, A.; de Kock, L.; Sabbaghian, N.; Apellaniz-Ruiz, M.; Bozkurt, C.; Bouron-Dal Soglio, D.;
Foulkes, W.D. A case of neuroblastoma in DICER1 syndrome: Chance finding or noncanonical causation?
Pediatr. Blood Cancer 2018, 65, e26715. [CrossRef] [PubMed]
11. Bernstein, E.; Caudy, A.A.; Hammond, S.M.; Hannon, G.J. Role for a bidentate ribonuclease in the initiation
step of RNA interference. Nature 2001, 409, 363–366. [CrossRef] [PubMed]
12. Murray, M.J.; Bailey, S.; Raby, K.L.; Saini, H.K.; de Kock, L.; Burke, G.A.A.; Foulkes, W.D.; Enright, A.J.;
Coleman, N.; Tischkowitz, M. Serum levels of mature microRNAs in DICER1-mutated pleuropulmonary
blastoma. Oncogenesis 2014, 3, e87. [CrossRef] [PubMed]
13. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell 1993, 75, 843–854. [CrossRef]
Cancers 2018, 10, 143 13 of 17
14. Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4
mediates temporal pattern formation in C. elegans. Cell 1993, 75, 855–862. [CrossRef]
15. Hammond, S.M. Dicing and slicing. FEBS Lett. 2005, 579, 5822–5829. [CrossRef] [PubMed]
16. Catalanotto, C.; Cogoni, C.; Zardo, G. MicroRNA in Control of Gene Expression: An Overview of Nuclear
Functions. Int. J. Mol. Sci. 2016, 17, 1712. [CrossRef] [PubMed]
17. Jansson, M.D.; Lund, A.H. MicroRNA and cancer. Mol. Oncol. 2012, 6, 590–610. [CrossRef] [PubMed]
18. Kian, R.; Moradi, S.; Ghorbian, S. Role of components of microRNA machinery in carcinogenesis. Exp. Oncol.
2018, 40, 2–9. [PubMed]
19. Song, M.; Rossi, J.J. Molecular mechanisms of DICER: Endonuclease and enzymatic activity. Biochem. J. 2017,
474, 1603–1618. [CrossRef] [PubMed]
20. Matskevich, A.A.; Moelling, K. Stimuli-dependent cleavage of DICER during apoptosis. Biochem. J. 2008,
412, 527–534. [CrossRef] [PubMed]
21. De Kock, L.; Wang, Y.C.; Revil, T.; Badescu, D.; Rivera, B.; Sabbaghian, N.; Wu, M.; Weber, E.; Sandoval, C.;
Hopman, S.M.J.; et al. High-sensitivity sequencing reveals multi-organ somatic mosaicism causing DICER1
syndrome. J. Med. Genet. 2016, 53, 43–52. [CrossRef] [PubMed]
22. Home-PubMed-NCBI. Available online: https://www.ncbi.nlm.nih.gov/pubmed (accessed on 19 April 2017).
23. Khan, N.E.; Bauer, A.J.; Schultz, K.A.P.; Doros, L.; Decastro, R.M.; Ling, A.; Lodish, M.B.; Harney, L.A.;
Kase, R.G.; Carr, A.G.; et al. Quantification of Thyroid Cancer and Multinodular Goiter Risk in the DICER1
Syndrome: A Family-Based Cohort Study. J. Clin. Endocrinol. Metab. 2017, 102, 1614–1622. [CrossRef]
[PubMed]
24. Apellaniz-Ruiz, M.; de Kock, L.; Sabbaghian, N.; Guaraldi, F.; Ghizzoni, L.; Beccuti, G.; Foulkes, W.D.
Familial multinodular goiter and Sertoli-Leydig cell tumors associated with a large intragenic in-frame
DICER1 deletion. Eur. J. Endocrinol. 2018, 178, K11–K19. [CrossRef] [PubMed]
25. Cancer of the Thyroid—Cancer Stat Facts. Available online: https://seer.cancer.gov/statfacts/html/thyro.html
(accessed on 19 April 2017).
26. Zarkesh, M.; Zadeh-Vakili, A.; Azizi, F.; Foroughi, F.; Akhavan, M.M.; Hedayati, M. Altered Epigenetic
Mechanisms in Thyroid Cancer Subtypes. Mol. Diagn. Ther. 2017, 22, 41–46. [CrossRef] [PubMed]
27. Knudsen, N.; Laurberg, P.; Perrild, H.; Bülow, I.; Ovesen, L.; Jørgensen, T. Risk Factors for Goiter and Thyroid
Nodules. Thyroid 2002, 12, 879–888. [CrossRef] [PubMed]
28. Darrat, I.; Bedoyan, J.K.; Chen, M.; Schuette, J.L.; Lesperance, M.M. Novel DICER1 mutation as cause of
multinodular goiter in children. Head Neck 2013. [CrossRef] [PubMed]
29. De Kock, L.; Bah, I.; Brunet, J.; Druker, H.; Astigarraga, I.; Bosch-Barrera, J.; Soglio, D.B.-D.; Nguyen, V.-H.;
Malkin, D.; Priest, J.R.; et al. Somatic DICER1 mutations in adult-onset pulmonary blastoma. Eur. Respir. J.
2016, 47, 1879–1882. [CrossRef] [PubMed]
30. Dishop, M.K.; Kuruvilla, S. Primary and metastatic lung tumors in the pediatric population: A review and
25-year experience at a large children’s hospital. Arch. Pathol. Lab. Med. 2008, 132, 1079–1103. [PubMed]
31. Manivel, J.C.; Priest, J.R.; Watterson, J.; Steiner, M.; Woods, W.G.; Wick, M.R.; Dehner, L.P. Pleuropulmonary
blastoma. The so-called pulmonary blastoma of childhood. Cancer 1988, 62, 1516–1526. [CrossRef]
32. Fosdal, M.B. Pleuropulmonary Blastoma. J. Pediatr. Oncol. Nurs. 2008, 25, 295–302. [CrossRef] [PubMed]
33. Priest, J.R.; Magnuson, J.; Williams, G.M.; Abromowitch, M.; Byrd, R.; Sprinz, P.; Finkelstein, M.; Moertel, C.L.;
Hill, D.A. Cerebral metastasis and other central nervous system complications of pleuropulmonary blastoma.
Pediatr. Blood Cancer 2007, 49, 266–273. [CrossRef] [PubMed]
34. Schultz, K.A.P.; Harris, A.; Messinger, Y.; Sencer, S.; Baldinger, S.; Dehner, L.P.; Hill, D.A. Ovarian tumors
related to intronic mutations in DICER1: A report from the international ovarian and testicular stromal
tumor registry. Fam. Cancer 2016, 15, 105–110. [CrossRef] [PubMed]
35. Doros, L.; Yang, J.; Dehner, L.; Rossi, C.T.; Skiver, K.; Jarzembowski, J.A.; Messinger, Y.; Schultz, K.A.;
Williams, G.; André, N.; Hill, D.A. DICER1 Mutations in embryonal rhabdomyosarcomas from children with
and without familial PPB-tumor predisposition syndrome. Pediatr. Blood Cancer 2012, 59, 558–560. [CrossRef]
[PubMed]
36. Stewart, D.R.; Messinger, Y.; Williams, G.M.; Yang, J.; Field, A.; Schultz, K.A.P.; Harney, L.A.; Doros, L.A.;
Dehner, L.P.; Hill, D.A. Nasal chondromesenchymal hamartomas arise secondary to germline and somatic
mutations of DICER1 in the pleuropulmonary blastoma tumor predisposition disorder. Hum. Genet. 2014,
133, 1443–1450. [CrossRef] [PubMed]
Cancers 2018, 10, 143 14 of 17
37. de Kock, L.; Sabbaghian, N.; Soglio, D.B.D.; Guillerman, R.P.; Park, B.K.; Chami, R.; Deal, C.L.; Priest, J.R.;
Foulkes, W.D. Exploring the association between DICER1 mutations and differentiated thyroid carcinoma.
J. Clin. Endocrinol. Metab. 2014, 99, E1072-7. [CrossRef] [PubMed]
38. Palculict, T.B.; Ruteshouser, E.C.; Fan, Y.; Wang, W.; Strong, L.; Huff, V. Identification of germline DICER1
mutations and loss of heterozygosity in familial Wilms tumour. J. Med. Genet. 2015, 53, 1–4.
39. Bahubeshi, A.; Bal, N.; Rio Frio, T.; Hamel, N.; Pouchet, C.; Yilmaz, A.; Bouron-Dal Soglio, D.; Williams, G.M.;
Tischkowitz, M.; Priest, J.R.; et al. Germline DICER1 mutations and familial cystic nephroma. J. Med. Genet.
2010, 47, 863–866. [CrossRef] [PubMed]
40. De Kock, L.; Plourde, F.; Carter, M.T.; Hamel, N.; Srivastava, A.; Meyn, M.S.; Arseneau, J.; Soglio, D.B.-D.;
Foulkes, W.D. Germ-line and somatic DICER1 mutations in a pleuropulmonary blastoma. Pediatr. Blood Cancer
2013, 60, 2091–2092. [CrossRef] [PubMed]
41. Kuhlen, M.; Hönscheid, A.; Schemme, J.; Merz, H.; Mauz-Körholz, C.; Borkhardt, A.; Troeger, A. Hodgkin
lymphoma as a novel presentation of familial DICER1 syndrome. Eur. J. Pediatr. 2016, 175, 593–597.
[CrossRef] [PubMed]
42. Rath, S.R.; Bartley, A.; Charles, A.; Powers, N.; Baynam, G.; Jones, T.; Priest, J.R.; Foulkes, W.D.; Choong, C.S.Y.
Multinodular Goiter in children: An important pointer to a germline DICER1 mutation. J. Clin.
Endocrinol. Metab. 2014, 99, 1947–1948. [CrossRef] [PubMed]
43. Fernández-Martínez, L.; Villegas, J.A.; Santamaría, Í.; Pitiot, A.S.; Alvarado, M.G.; Fernández, S.;
Torres, H.; Paredes, Á.; Blay, P.; Balbín, M. Identification of somatic and germ-line DICER1 mutations
in pleuropulmonary blastoma, cystic nephroma and rhabdomyosarcoma tumors within a DICER1 syndrome
pedigree. BMC Cancer 2017, 17, 146. [CrossRef] [PubMed]
44. Doros, L.A.; Rossi, C.T.; Yang, J.; Field, A.; Williams, G.M.; Messinger, Y.; Cajaiba, M.M.; Perlman, E.J.;
Schultz, K.A.; Cathro, H.P.; et al. DICER1 mutations in childhood cystic nephroma and its relationship to
DICER1-renal sarcoma. Mod. Pathol. 2014, 27, 1267–1280. [CrossRef] [PubMed]
45. Boman, F.; Hill, D.A.; Williams, G.M.; Chauvenet, A.; Fournet, J.-C.; Soglio, D.B.-D.; Messinger, Y.; Priest, J.R.
Familial association of pleuropulmonary blastoma with cystic nephroma and other renal tumors: A report
from the International Pleuropulmonary Blastoma Registry. J. Pediatr. 2006, 149, 850–854. [CrossRef]
[PubMed]
46. Cai, S.; Zhao, W.; Nie, X.; Abbas, A.; Fu, L.; Bihi, S.; Feng, G.; Liu, T.; Lv, Y.; Ma, X.; et al. Multimorbidity and
Genetic Characteristics of DICER1 Syndrome Based on Systematic Review. J. Pediatr. Hematol. Oncol. 2016,
39, 355–361. [CrossRef] [PubMed]
47. Turbiner, J.; Amin, M.B.; Humphrey, P.A.; Srigley, J.R.; De Leval, L.; Radhakrishnan, A.; Oliva, E. Cystic
nephroma and mixed epithelial and stromal tumor of kidney: A detailed clinicopathologic analysis of
34 cases and proposal for renal epithelial and stromal tumor (REST) as a unifying term. Am. J. Surg. Pathol.
2007, 31, 489–500. [CrossRef] [PubMed]
48. Bal, N.; Kayaselçuk, F.; Polat, A.; Bolat, F.; Yilmaz, Z.; Tuncer, I. Familial cystic nephroma in two siblings
with pleuropulmonary blastoma. Pathol. Oncol. Res. 2005, 11, 53–56. [CrossRef] [PubMed]
49. Kuzgunbay, B.; Turunc, T.; Bolat, F.; Kilinc, F. Adult cystic nephroma: A case report and a review of the
literature. Urol. Oncol. 2009, 27, 407–409. [CrossRef] [PubMed]
50. Paal, E.; Thompson, L.D.; Heffess, C.S. A clinicopathologic and immunohistochemical study of ten pancreatic
lymphangiomas and a review of the literature. Cancer 1998, 82, 2150–2158. [CrossRef]
51. Bastian, P.J.; Kuhlmann, R.; Vogel, J.; Bastian, H.-P. Local recurrence of a unilateral cystic nephroma.
Int. J. Urol. 2004, 11, 329–331. [CrossRef] [PubMed]
52. Wu, M.K.; Cotter, M.B.; Pears, J.; McDermott, M.B.; Fabian, M.R.; Foulkes, W.D.; O’Sullivan, M.J. Tumor
progression in DICER1-mutated cystic nephroma-witnessing the genesis of anaplastic sarcoma of the kidney.
Hum. Pathol. 2016, 53, 114–120. [CrossRef] [PubMed]
53. Wu, M.K.; Vujanic, G.M.; Fahiminiya, S.; Watanabe, N.; Thorner, P.S.; O’Sullivan, M.J.; Fabian, M.R.;
Foulkes, W.D. Anaplastic sarcomas of the kidney are characterized by DICER1 mutations. Mod. Pathol. 2018,
31, 169–178. [CrossRef] [PubMed]
54. Croce, S.; de Kock, L.; Boshari, T.; Hostein, I.; Velasco, V.; Foulkes, W.D.; McCluggage, W.G. Uterine Tumor
Resembling Ovarian Sex Cord Tumor (UTROSCT) Commonly Exhibits Positivity With Sex Cord Markers
FOXL2 and SF-1 but Lacks FOXL2 and DICER1 Mutations. Int. J. Gynecol. Pathol. 2016, 35, 301–308.
[CrossRef] [PubMed]
Cancers 2018, 10, 143 15 of 17
55. Lim, D.; Oliva, E. Ovarian sex cord-stromal tumours: An update in recent molecular advances. Pathology
2018, 50, 178–189. [CrossRef] [PubMed]
56. Nwogu, L.C.; Showalter, J.A.; Roy, S.; Deavers, M.T.; Zhao, B. Retiform Sertoli-Leydig Cell Tumor in a
38-Year-Old Woman: A Case Report, Retrospective Review, and Review of Current Literature. Case Rep. Pathol.
2017, 2017, 3421832. [CrossRef] [PubMed]
57. Conlon, N.; Schultheis, A.M.; Piscuoglio, S.; Silva, A.; Guerra, E.; Tornos, C.; Reuter, V.E.; Soslow, R.A.;
Young, R.H.; Oliva, E.; et al. A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal
tumors. Mod. Pathol. 2015, 28, 1603–1612. [CrossRef] [PubMed]
58. De Kock, L.; Terzic, T.; McCluggage, W.G.; Stewart, C.J.R.; Shaw, P.; Foulkes, W.D.; Clarke, B.A. DICER1
Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors.
Am. J. Surg. Pathol. 2017, 41, 1178–1187. [CrossRef] [PubMed]
59. Sigismondi, C.; Gadducci, A.; Lorusso, D.; Candiani, M.; Breda, E.; Raspagliesi, F.; Cormio, G.; Marinaccio, M.;
Mangili, G. Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study. Gynecol. Oncol. 2012, 125,
673–676. [CrossRef] [PubMed]
60. Mooney, E.E.; Nogales, F.F.; Bergeron, C.; Tavassoli, F.A. Retiform Sertoli-Leydig cell tumours: Clinical,
morphological and immunohistochemical findings. Histopathology 2002, 41, 110–117. [CrossRef] [PubMed]
61. Bellfield, E.J.; Alemzadeh, R. Recurrent ovarian Sertoli-Leydig cell tumor in a child with Peutz-Jeghers
syndrome. Oxford Med. 2016, 2016. [CrossRef] [PubMed]
62. Durieux, E.; Descotes, F.; Mauduit, C.; Decaussin, M.; Guyetant, S.; Devouassoux-Shisheboran, M.
The co-occurrence of an ovarian Sertoli-Leydig cell tumor with a thyroid carcinoma is highly suggestive of a
DICER1 syndrome. Virchows Arch. 2016, 468, 631–636. [CrossRef] [PubMed]
63. Oost, E.E.; Charles, A.; Choong, C.S.; Leung, Y.C.; Salfinger, S.; Sonnendecker, H.; Tan, J.; Townshend, S.;
Witkowski, L.; Foulkes, W.D.; et al. Ovarian sex cord-stromal tumors in patients with probable or confirmed
germline DICER1 mutations. Int. J. Gynecol. Pathol. 2015, 34, 266–274. [CrossRef] [PubMed]
64. Sabbaghian, N.; Srivastava, A.; Hamel, N.; Plourde, F.; Gajtko-Metera, M.; Niedziela, M.; Foulkes, W.D.
Germ-line deletion in DICER1 revealed by a novel MLPA assay using synthetic oligonucleotides. Eur. J.
Hum. Genet. 2014, 22, 564–567. [CrossRef] [PubMed]
65. De Kock, L.; Bah, I.; Wu, Y.; Xie, M.; Priest, J.R.; Foulkes, W.D. Germline and somatic DICER1 mutations
in a well-differentiated fetal adenocarcinoma of the lung. J. Thorac. Oncol. 2016, 11, e31–e33. [CrossRef] [PubMed]
66. Wu, Y.; Chen, D.; Li, Y.; Bian, L.; Ma, T.; Xie, M. DICER1 mutations in a patient with an ovarian Sertoli-Leydig
tumor, well-differentiated fetal adenocarcinoma of the lung, and familial multinodular goiter. Eur. J.
Med. Genet. 2014, 57, 621–625. [CrossRef] [PubMed]
67. Rossing, M.; Gerdes, A.-M.; Juul, A.; Rechnitzer, C.; Rudnicki, M.; Nielsen, F.C.; Vo Hansen, T. A novel
DICER1 mutation identified in a female with ovarian Sertoli-Leydig cell tumor and multinodular goiter:
A case report. J. Med. Case Rep. 2014, 8, 112. [CrossRef] [PubMed]
68. Foulkes, W.D.; Bahubeshi, A.; Hamel, N.; Pasini, B.; Asioli, S.; Baynam, G.; Choong, C.S.; Charles, A.;
Frieder, R.P.; Dishop, M.K.; et al. Extending the phenotypes associated with DICER1 mutations. Hum. Mutat.
2011, 32, 1381–1384. [CrossRef] [PubMed]
69. De Kock, L.; Sabbaghian, N.; Druker, H.; Weber, E.; Hamel, N.; Miller, S.; Choong, C.S.; Gottardo, N.G.;
Kees, U.R.; Rednam, S.P.; et al. Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol.
2014, 128, 583–595. [CrossRef] [PubMed]
70. Sabbaghian, N.; Hamel, N.; Srivastava, A.; Albrecht, S.; Priest, J.R.; Foulkes, W.D. Germline DICER1 mutation
and associated loss of heterozygosity in a pineoblastoma. J. Med. Genet. 2012, 49, 417–419. [CrossRef]
[PubMed]
71. De Kock, L.; Druker, H.; Weber, E.; Hamel, N.; Traubici, J.; Malkin, D.; Arseneau, J.; Stewart, C.J.R.;
Bouron-Dal Soglio, D.; Priest, J.R.; et al. Ovarian embryonal rhabdomyosarcoma is a rare manifestation of
the DICER1 syndrome. Hum. Pathol. 2015, 46, 917–922. [CrossRef] [PubMed]
72. De Kock, L.; Sabbaghian, N.; Plourde, F.; Srivastava, A.; Weber, E.; Bouron-Dal Soglio, D.; Hamel, N.;
Choi, J.H.; Park, S.-H.; Deal, C.L.; et al. Pituitary blastoma: A pathognomonic feature of germ-line DICER1
mutations. Acta Neuropathol. 2014, 128, 111–122. [CrossRef] [PubMed]
73. Mehraein, Y.; Schmid, I.; Eggert, M.; Kohlhase, J.; Steinlein, O.K. DICER1 syndrome can mimic different
genetic tumor predispositions. Cancer Lett. 2016, 370, 275–278. [CrossRef] [PubMed]
Cancers 2018, 10, 143 16 of 17
74. Wu, M.K.; Goudie, C.; Druker, H.; Thorner, P.; Traubici, J.; Grant, R.; Albrecht, S.; Weber, E.; Charles, A.;
Priest, J.R.; et al. Evolution of Renal Cysts to Anaplastic Sarcoma of Kidney in a Child With DICER1
Syndrome. Pediatr. Blood Cancer 2016, 63, 1272–1275. [CrossRef] [PubMed]
75. Caruso, S.; Calderaro, J.; Letouzé, E.; Nault, J.-C.; Couchy, G.; Boulais, A.; Luciani, A.; Zafrani, E.-S.;
Bioulac-Sage, P.; Seror, O.; et al. Germline and somatic DICER1 mutations in familial and sporadic liver
tumors. J. Hepatol. 2016, 66, 734–742. [CrossRef] [PubMed]
76. De Kock, L.; Boshari, T.; Martinelli, F.; Wojcik, E.; Niedziela, M.; Foulkes, W.D. Adult-Onset Cervical
Embryonal Rhabdomyosarcoma and DICER1 Mutations. J. Low. Genit. Tract Dis. 2016, 20, e8–e10. [CrossRef]
[PubMed]
77. Sahakitrungruang, T.; Srichomthong, C.; Pornkunwilai, S.; Amornfa, J.; Shuangshoti, S.; Kulawonganunchai, S.;
Suphapeetiporn, K.; Shotelersuk, V. Germline and somatic DICER1 mutations in a pituitary blastoma causing
infantile-onset Cushing’s disease. J. Clin. Endocrinol. Metab. 2014, 99, E1487-92. [CrossRef] [PubMed]
78. Yang, L.; Wang, G.; Zhao, X.; Ye, S.; Shen, P.; Wang, W.; Zheng, S. A novel WRN frameshift mutation
identified by multiplex genetic testing in a family with multiple cases of cancer. PLoS ONE 2015, 10, e0133020.
[CrossRef] [PubMed]
79. Fremerey, J.; Balzer, S.; Brozou, T.; Schaper, J.; Borkhardt, A.; Kuhlen, M. Embryonal rhabdomyosarcoma in
a patient with a heterozygous frameshift variant in the DICER1 gene and additional manifestations of the
DICER1 syndrome. Fam. Cancer 2017, 16, 401–405. [CrossRef] [PubMed]
80. Tomiak, E.; de Kock, L.; Grynspan, D.; Ramphal, R.; Foulkes, W.D. DICER1 mutations in an adolescent
with cervical embryonal rhabdomyosarcoma (cERMS). Pediatr. Blood Cancer 2014, 61, 568–569. [CrossRef]
[PubMed]
81. Bardón-Cancho, E.J.; Haro-Díaz, A.; Alonso-García-de la Rosa, F.J.; Huerta-Aragonés, J.; García-Morín, M.;
González-Martínez, F.; Garrido-Colino, C. DICER1 mutation and tumors associated with a familial tumor
predisposition syndrome: Practical considerations. Fam. Cancer 2016, 16, 291–294. [CrossRef] [PubMed]
82. Yoshida, M. Metachronous anaplastic sarcoma of the kidney and thyroid follicular carcinoma as
manifestations of DICER1 abnormalities. Endocr. Relat. Cancer 2016, 23, L1–L5. [CrossRef] [PubMed]
83. Wu, M.K.; de Kock, L.; Conwell, L.S.; Stewart, C.J.R.; King, B.R.; Choong, C.S.; Hussain, K.; Sabbaghian, N.;
MacRae, I.J.; Fabian, M.R.; et al. Functional characterization of multiple DICER1 mutations in an adolescent.
Endocr. Relat. Cancer 2016, 23, L1–L5. [CrossRef] [PubMed]
84. Klein, S.; Lee, H.; Ghahremani, S.; Kempert, P.; Ischander, M.; Teitell, M.A.; Nelson, S.F.; Martinez-Agosto, J.A.
Expanding the phenotype of mutations in DICER1: Mosaic missense mutations in the RNase IIIb domain of
DICER1 cause GLOW syndrome. J. Med. Genet. 2014, 51, 294–302. [CrossRef] [PubMed]
85. Khan, N.E.; Bauer, A.J.; Doros, L.; Schultz, K.A.P.; Decastro, R.M.; Harney, L.A.; Kase, R.G.; Carr, A.G.;
Harris, A.K.; Williams, G.M.; et al. Macrocephaly associated with the DICER1 syndrome. Genet. Med. 2017,
19, 244–248. [CrossRef] [PubMed]
86. Nordling, C.O. A new theory on cancer-inducing mechanism. Br. J. Cancer 1953, 7, 68–72. [CrossRef] [PubMed]
87. Knudson, A.G. Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 1971, 68,
820–823. [CrossRef] [PubMed]
88. Davis, J.; Eyre, H.; Jacka, F.N.; Dodd, S.; Dean, O.; McEwen, S.; Debnath, M.; McGrath, J.; Maes, M.;
Amminger, P.; et al. A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis.
Proc. Natl. Acad. Sci. USA 2016, 65, 185–194. [CrossRef] [PubMed]
89. Berthon, A.; Faucz, F.; Bertherat, J.; Stratakis, C.A. Analysis of ARMC5 expression in human tissues.
Mol. Cell. Endocrinol. 2017, 441, 140–145. [CrossRef] [PubMed]
90. Wu, M.K.; Sabbaghian, N.; Xu, B.; Addidou-Kalucki, S.; Bernard, C.; Zou, D.; Reeve, A.E.; Eccles, M.R.;
Cole, C.; Choong, C.S.; et al. Biallelic DICER1 mutations occur in Wilms tumours. J. Pathol. 2013, 230,
154–164. [CrossRef] [PubMed]
91. Anglesio, M.; Wang, Y.; Yang, W.; Senz, J.; Wan, A.; Heravi-Moussavi, A.; Salamanca, C.; Maines-Bandiera, S.;
Huntsman, D.; Morin, G. Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA
processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand
cleavage. J. Pathol. 2013, 229, 400–409. [CrossRef] [PubMed]
92. De Kock, L.; Bah, I.; Revil, T.; Bérubé, P.; Wu, M.K.; Sabbaghian, N.; Priest, J.R.; Ragoussis, J.; Foulkes, W.D.
Deep Sequencing Reveals Spatially Distributed Distinct Hot Spot Mutations in DICER1-Related Multinodular
Goiter. J. Clin. Endocrinol. Metab. 2016, 101, 3637–3645. [CrossRef] [PubMed]
Cancers 2018, 10, 143 17 of 17
93. Seki, M.; Yoshida, K.; Shiraishi, Y.; Shimamura, T.; Sato, Y.; Nishimura, R.; Okuno, Y.; Chiba, K.; Tanaka, H.;
Kato, K.; et al. Biallelic DICER1 mutations in sporadic pleuropulmonary blastoma. Cancer Res. 2014, 74,
2742–2749. [CrossRef] [PubMed]
94. Melendez-Zajgla, J.; Mercado-Celis, G.E.; Gaytan-Cervantes, J.; Torres, A.; Gabiño, N.B.; Zapata-Tarres, M.;
Juarez-Villegas, L.E.; Lezama, P.; Maldonado, V.; Ruiz-Monroy, K.; et al. Genomics of a pediatric ovarian
fibrosarcoma. Association with the DICER1 syndrome. Sci. Rep. 2018, 8, 3252. [CrossRef] [PubMed]
95. Brenneman, M.; Field, A.; Yang, J.; Williams, G.; Doros, L.; Rossi, C.; Schultz, K.A.; Rosenberg, A.;
Ivanovich, J.; Turner, J.; et al. Temporal order of RNase IIIb and loss-of-function mutations during
development determines phenotype in DICER1 syndrome: A unique variant of the two-hit tumor
suppression model. F1000Research 2015, 4, 214. [CrossRef] [PubMed]
96. Chen, J.; Wang, Y.; McMonechy, M.K.; Anglesio, M.S.; Yang, W.; Senz, J.; Maines-Bandiera, S.; Rosner, J.;
Trigo-Gonzalez, G.; Grace Cheng, S.W.; et al. Recurrent DICER1 hotspot mutations in endometrial tumours
and their impact on microRNA biogenesis. J. Pathol. 2015, 237, 215–225. [CrossRef] [PubMed]
97. Blandino, G.; Valerio, M.; Cioce, M.; Mori, F.; Casadei, L.; Pulito, C.; Sacconi, A.; Biagioni, F.; Cortese, G.;
Galanti, S.; et al. Metformin elicits anticancer effects through the sequential modulation of DICER and
c-MYC. Nat. Commun. 2012, 3, 865. [CrossRef] [PubMed]
98. Noren Hooten, N.; Martin-Montalvo, A.; Dluzen, D.F.; Zhang, Y.; Bernier, M.; Zonderman, A.B.; Becker, K.G.;
Gorospe, M.; de Cabo, R.; Evans, M.K. Metformin-mediated increase in DICER1 regulates microRNA
expression and cellular senescence. Aging Cell 2016, 15, 572–581. [CrossRef] [PubMed]
99. Wu, X.; Yang, Y.; Huang, Y.; Chen, Y.; Wang, T.; Wu, S.; Tong, L.; Wang, Y.; Lin, L.; Hao, M.; et al. RNA-binding
protein AUF1 suppresses miR-122 biogenesis by down-regulating DICER1 in hepatocellular carcinoma.
Oncotarget 2018, 9, 14815–14827. [CrossRef] [PubMed]
100. Oxford, A.E.; Jorcyk, C.L.; Oxford, J.T. Neuropathies of Stüve-Wiedemann Syndrome due to mutations in
leukemia inhibitory factor receptor (LIFR) gene. J. Neurol. Neuromedicine 2016, 1, 37–44. [CrossRef] [PubMed]
101. Welch, E.M.; Barton, E.R.; Zhuo, J.; Tomizawa, Y.; Friesen, W.J.; Trifillis, P.; Paushkin, S.; Patel, M.; Trotta, C.R.;
Hwang, S.; et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447, 87–91.
[CrossRef] [PubMed]
102. Pibiri, I.; Lentini, L.; Melfi, R.; Gallucci, G.; Pace, A.; Spinello, A.; Barone, G.; Di Leonardo, A. Enhancement
of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives. Eur. J. Med. Chem.
2015, 101, 236–244. [CrossRef] [PubMed]
103. Verrier, F.; Dubois d’Enghien, C.; Gauthier-Villars, M.; Bonadona, V.; Faure-Conter, C.; Dijoud, F.;
Stoppa-Lyonnet, D.; Houdayer, C.; Golmard, L. Mutiple DICER1-related lesions associated with a germline
deep intronic mutation. Pediatr. Blood Cancer 2018, e27005. [CrossRef] [PubMed]
104. Diets, I.J.; Waanders, E.; Ligtenberg, M.J.; van Bladel, D.A.G.; Kamping, E.J.; Hoogerbrugge, P.M.; Hopman, S.;
Olderode-Berends, M.J.; Gerkes, E.H.; Koolen, D.A.; et al. High Yield of Pathogenic Germline Mutations
Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer. Clin. Cancer Res.
2018, 24, 1594–1603. [CrossRef] [PubMed]
105. Nikiforova, M.N.; Mercurio, S.; Wald, A.I.; Barbi de Moura, M.; Callenberg, K.; Santana-Santos, L.;
Gooding, W.E.; Yip, L.; Ferris, R.L.; Nikiforov, Y.E. Analytical performance of the ThyroSeq v3 genomic
classifier for cancer diagnosis in thyroid nodules. Cancer 2018. [CrossRef] [PubMed]
106. Schultz, K.A.P.; Williams, G.M.; Kamihara, J.; Stewart, D.R.; Harris, A.K.; Bauer, A.J.; Turner, J.; Shah, R.;
Schneider, K.; Schneider, K.W.; et al. DICER1 and Associated Conditions: Identification of At-risk Individuals
and Recommended Surveillance Strategies. Clin. Cancer Res. 2018. [CrossRef] [PubMed]
107. Wasserman, J.D.; Sabbaghian, N.; Fahiminiya, S.; Chami, R.; Mete, O.; Acker, M.; Wu, M.K.; Shlien, A.; de
Kock, L.; Foulkes, W.D. DICER1 mutations are frequent in adolescent-onset papillary thyroid carcinoma. J.
Clin. Endocrinol. Metab. 2018, 103, 2009–2015. [CrossRef] [PubMed]
108. Van Engelen, K.; Villani, A.; Wasserman, J.D.; Aronoff, L.; Greer, M.-L.C.; Tijerin Bueno, M.; Gallinger, B.;
Kim, R.H.; Grant, R.; Meyn, M.S.; et al. DICER1 syndrome: Approach to testing and management at a large
pediatric tertiary care center. Pediatr. Blood Cancer 2018, 65, e26720. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
